Effects of sulfamethoxazole on murine ocular toxoplasmosis in interferon-γ knockout mice

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 1, 2006, Pages 265-271

  Norose, Kazumi ^a   Aosai, Fumie ^a   Mun, Hye Seong ^a   Yano, Akihiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; SULFAMETHOXAZOLE; ANTIINFECTIVE AGENT; PROTOZOAL DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYZOITE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; MORTALITY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXOPLASMA GONDII; TOXOPLASMOSIS; ANIMAL; ANIMAL PARASITOSIS; BAGG ALBINO MOUSE; C57BL MOUSE; CHORIORETINITIS; FEMALE; GENETICS; MALE; MOUSE MUTANT; PARASITEMIA; PARASITOLOGY; SURVIVAL RATE; TOXOPLASMA;

ANIMALS; ANTI-INFECTIVE AGENTS; CHORIORETINITIS; DNA, PROTOZOAN; FEMALE; INTERFERON TYPE II; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PARASITEMIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFAMETHOXAZOLE; SURVIVAL RATE; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; TOXOPLASMOSIS, OCULAR;

EID: 33644848113     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0751     Document Type: Article

References (37)

1. Gagliuso DJ, Teich SA, Friedman AH, Orellana J. Ocular toxoplasmosis in AIDS patients. Trans Am Ophthalmol Soc. 1990;88:63-86; discussion 86-88.
2. Nicholson DH, Wolchok EB. Ocular toxoplasmosis in an adult receiving long-term corticosteroid therapy. Arch Ophthalmol. 1976;94:248-254.
3. Singer MA, Hagler WS, Grossniklaus HE. Toxoplasma gondii retinochoroiditis after liver transplantation. Retina. 1993;13:40-45.
4. Israelski DM, Remington JS. Toxoplasmosis in the non-AIDS immunocompromised host. Curr Clin Top Infect Dis. 1993;13:322-356.
5. Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology. 2003;110:926-931; quiz 931-932.
6. Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115:517-523.
7. Silveira C, Belfort R Jr, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134:41-46.
8. Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004;137:1-17.
9. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis (published correction in Am J Ophthalmol. 2002;134:944). Am J Ophthalmol. 2002;134:102-114.
10. Engstrom RE Jr, Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111:601-610.
11. Leport C, Chêne G, Morlat P, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. J Infect Dis. 1996;173:91-97.
12. Gormley PD, Pavesio CE, Minnasian D, Lightman S. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Invest Ophthalmol Vis Sci. 1998;39:1171-1175.
13. Tabbara KF, Nozik RA, O'Connor GR. Clindamycin effects on experimental ocular toxoplasmosis in the rabbit. Arch Ophthalmol. 1974;92:244-247.
14. Norose K, Mun HS, Aosai F, et al. IFN-γ-regulated Toxoplasma gondii distribution and load in the murine eye. Invest Ophthalmol Vis Sci. 2003;44:4375-4381.
15. Norose K, Mun HS, Aosai F, et al. Organ infectivity of Toxoplasma gondii in interferon-γ knockout mice. J Parasitol. 2001;87:447-452.
16. -/- mice: role for IFN-γ in activating apoptosis of hepatocytes. J Immunol. 1997;159:1418-1428.
17. Luo W, Aosai F, Ueda M, et al. Kinetics in parasite abundance in susceptible and resistant mice infected with an avirulent strain of Toxoplasma gondii by using quantitative competitive PCR. J Parasitol. 1997;83:1070-1074.
18. Burg JL, Perelman D, Kasper LH, Ware PL, Boothroyd JC. Molecular analysis of the gene encoding the major surface antigen of Toxoplasma gondii. J Immunol. 1988;141:3584-3591.
19. Bohne W, Gross U, Ferguson DJ, Heesemann J. Cloning and characterization of a bradyzoite-specifically expressed gene (hsp30/ bag1) of Toxoplasma gondii, related to genes encoding small heat-shock proteins of plants. Mol Microbiol. 1995;16:1221-1230.
20. Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. 1998;42:1346-1349.
21. Remington JS. Trimethoprim-sulfamethoxazole in murine toxoplasmosis. Antimicrob Agents Chemother. 1976;9:222-223.
22. van der Ven AJAM, Schoondermark-van de Ven EME, Camps W, et al. Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. J Antimicrob Chemother. 1996;38:75-80.
23. Eyles DE, Coleman N. Synergistic effect of sulfadiazine and daraprim against experimental toxoplasmosis in the mouse. Antibiot Chemother. 1953;3:483-490.
24. Piketty C, Derouin F, Rouveix B, Pocidalo JJ. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother. 1990;34:1467-1472.
25. Miédougé M, Bessiéres MH, Cassaing S, Swierczynski B, Séguéla JP. Parasitemia and parasitic loads in acute infection and after antigamma-interferon treatment in a toxoplasmic mouse model. Parasitol Res. 1997;83:339-344.
26. Feldmann HA. Effects of trimethoprim and sulfisoxazole alone and in combination on murine toxoplasmosis. J Infect Dis. 1973;128(suppl):S774- S776.
27. Dumas JL, Pizzolato G, Pechère JC. Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. Int J Antimicrob Agents. 1999;13:35-39.
28. Holland GN, O'Connor R, Belfort R Jr, Remington JS. Toxoplasmosis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St. Louis, MO: Mosby; 1996:1183-1223.
29. Belal US, Norose K, Aosai F, et al. Evaluation of the effects of sulfamethoxazole on Toxoplasma gondii loads and stage conversion in IFN-γ knockout mice using QC-PCR. Microbiol Immunol. 2004;48:185-193.
30. Dumas JL, Chang R, Mermillod B, Piguet PF, Comte R, Pechère JC. Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother. 1994;34:111-118.
31. Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991;164:170-177.
32. Dubey JP. Advances in the life cycle of Toxoplasma gondii. Int J Parasitol. 1998;28:1019-1024.
33. Bohne W, Holpert M, Gross U. Stage differentiation of the protozoan parasite Toxoplasma gondii. Immunobiology. 1999;201:248-254.
34. Sumyuen MH, Garin YJ, Derouin F. Effect of immunosuppressive drug regimens on acute and chronic murine toxoplasmosis. Parasitol Res. 1996;82:681-686.
35. Araujo FG, Williams DM, Grumet FC, Remington JS. Strain-dependent differences in murine susceptibility to toxoplasma. Infect Immun. 1976;13:1528-1530.
36. Kobayashi M, Aosai F, Hata H, et al. Toxoplasma gondii: difference of invasion into tissue of digestive organs between susceptible and resistant strain and influence of IFN-γ in mice inoculated with the cysts perorally. J Parasitol. 1999;85:973-975.
37. Sabbagh N, Delaporte E, Marez D, Lo-Guidice JM, Piette F, Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics. 1997;7:131-135.